## BISPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	17-Feb-2017	17-Feb-2020	: Date of Next Review
Prepared By:	Jamie Storm	16-000062 v3.0	: Supersedes
QA/QC Approval:	Nicole Fisher	Dora Meissner	: Management Approval
Reason for Revision:	See Revision History in ensur		

## TRIS HC1 Certificate of Analysis BIO Excipient Grade / TH3220-K012 LOT: TH3220-093-0919

NH<sub>2</sub>C(CH<sub>2</sub>OH)<sub>3</sub>. HCl  $\leftarrow$  F.W. 157.60 g/mol.  $\leftarrow$  CAS# 1185-53-1 Manufacturing Date: 9/18/2019 Retest Date: 9/30/2021

Packaging Date: 9/29/2019 Manufacturing Site: 1474 Rockdale Lane, Stroudsburg, PA 18360 Packaging Site: 100 Majestic Way, Bangor PA, 18013

ANALYSIS		SPECIFICATION	TEST RESULT	
Absorbance	280 nm	0.06 a.u. max.	0.0039a.u.	
Appearance and Color		White / Crystals	White / Crystals	
Assay		99.5% min.	99.63%	
	DNase	None Detected	None Detected	
Enzymes	RNase	None Detected	None Detected	
	Protease	None Detected	None Detected	
Heavy Metals		2 ppm max.	< 2 ppm	
Identification (IR)		Passes Test	Passes Test	
Insoluble Matter		0.001% max.	<0.0005%	
Karl Fischer		0.5% max.	0.34%	
Melting Range		150 – 153 °C	151.2-152.7°C	
pH (0.5M)		4.0 - 5.0	4.23 @ 23.2°C	
pKa		8.0 - 8.4	8.1	
Residue on Ignition		0.1% max.	<0.0298%	
Solubility		Passes Test	Passes Test	
Trace Elements	Arsenic (As)	1 ppm max.	< 1 ppm	
	Calcium (Ca)	1 ppm max.	< 1 ppm	
	Copper (Cu)	1 ppm max.	< 1 ppm	
	Iron (Fe)	1 ppm max.	< 1 ppm	
	Lead (Pb)	1 ppm max.	< 1 ppm	
	Magnesium (Mg)	1 ppm max.	< 1 ppm	

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping, and the prevention of unauthorized appropriation, use, disclosure and copying.

## COUNTRY OF ORIGIN: U.S.A.

## TEST METHOD REFERENCE: DCN: 16-000042

<u>INTENDED USE:</u> Material represented by this Certificate of Analysis is suitable to be used only as the following: ICH Q7 Compliant cGMP Manufactured Excipient for use in further manufacturing. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug Product or household item.

<u>RESIDUAL SOLVENTS</u>: Based on the manufacturing process and the controlled handling and storage of this product, there is no potential for any of the residual solvents listed in the current USP method <467> Tables 1, 2, 3, or 4 to be present at the specified limits; furthermore, if tested this product would comply with USP/NF requirements.

Prepared by:(		_Date: _	1017/19
	H. Bern	_Date: _	1017/19